International Consensus on Use of Continuous Glucose Monitoring
By Danne T, Nimri R, Battelino T, Bergenstal Rm, Close Kl, D. Jh, G. S., Heinemann L, Hirsch I, Amiel Sa and 24 more. Diabetes Care, 2017
1,833 citations recorded by the source corpus.
Measurement of glycated hemoglobin (HbA1c) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascular and macrovascular complications. Continuous glucose monitoring (CGM), either from real-time use (rtCGM) or intermittently viewed (iCGM), addresses many of the limitations inherent in HbA1c testing and self-monitoring of blood glucose. Although both provide the means to move beyond the HbA1c measurement as the sole marker of glycemic control, standardized metrics for analyzing CGM data are lacking. Moreover, clear criteria for matching people with diabetes to the most appropriate glucose monitoring methodologies, as well as standardized advice about how best to use the new information they provide, have yet to be established. In February 2017, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address these issues. This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics
View Paper: https://www.semanticscholar.org/paper/b34f9f8cc91488fda1311e524135c28265b0c79a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- A. Mobashsher
- W. Gonzales
- Zhaomian Li
- Amin Abbosh
- Adam S. Brown
- C. Kollman
- Tonya D. Riddlesworth
- Shaoyong Zheng
Citations in the corpus
- Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials (2018, background): “In the last year, several organizations published consensus statements on the role of CGM and specific metrics to use for assessing overall glycemic management, hyperglycemia, hypoglycemia, and glycemic variability (6,7), and a conference was held with representatives of all organizations to reach a”
- The Progress of Glucose Monitoring—A Review of Invasive to Minimally and Non-Invasive Techniques, Devices and Sensors (2019, background): “…is an independent and non-governmental organization that defines and develops specifications for procedures, services and production of high quality, reliable and safe products in a wide range of industries, including medical devices, food safety, environmental management and Information…”